$NUS

Nu Skin (NUS) reported Q3 2026 revenue of $311M, with adjusted EPS of $0.10. The company highlighted a 10% scan-to-purchase conversion rate and 3% year-to-date sales growth for LifePak. Nu Skin plans to launch innovations in anti-aging and women's health mid-2027 and is preparing for India's market entry in early 2027. The company is restructuring to improve efficiency and profitability, with a focus on East-West market alignment.

Nu Skin Enterprises reported Q3 2026 revenue of $311M and adjusted EPS of $0.10, meeting guidance. Core business faced pressure, but growth areas include Prysm engagement and India launch. Strategic restructuring and efficiency improvements are ongoing.

Nu Skin Enterprises (NUS) declared a $0.06 quarterly cash dividend payable on December 9, 2026, to shareholders of record as of November 27, 2026. The beauty and wellness company operates in nearly 50 markets worldwide.

Nu Skin Enterprises reported Q3 2026 revenue within guidance, but customer count fell 18%. Q4 revenue is projected at $310M-$340M. CEO Ryan Napierski cited strategic execution amid challenges. The company will host a conference call for investors.

NU SKIN ENTERPRISES, INC. (NUS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 17, 2026, Justin Keisel, the Executive Vice President and President of Global Sales of Nu Skin Enterprises

Nu Skin laid off 5% of its workforce, citing a 17.1% revenue decline in Q2 2026. CEO Ryan Napierski stated the move aims to drive long-term shareholder value. Separately, Tyson Foods closed its Eagle Mountain beef facility, affecting 723 jobs, due to strategic changes amid a cattle shortage.

Nu Skin Enterprises (NYSE:NUS) shares fell about 5% on Aug. 11, 2026 after its Q2 2026 results showed a net loss of $249.8 million versus a $21.1 million profit a year earlier, driven by goodwill impairment and a large U.S. deferred tax valuation allowance. Revenue was $320.1 million, down 17.1% YoY.

Stonegate Capital Partners updated coverage of NU Skin Enterprises (NUS) after 2Q26 results. Revenue was $320.1M versus an estimate of $345.2M; adjusted EPS was $0.20, matching estimates. GAAP EPS was $(5.14) due to $78.9M goodwill impairment and $167.5M deferred-tax valuation allowance. FY26 revenue guidance was cut to $1.28B-$1.35B and adjusted EPS to $0.70-$0.90.

Nu Skin Enterprises reported Q2 2026 results. Revenue was $320.1M and gross margin was 68.2% versus 68.8% in Q2 2025. Q3 revenue guidance is $310M to $340M with EPS $0 to $0.09. Full-year 2026 revenue is guided to $1.28B to $1.35B and adjusted EPS to $0.70 to $0.90, per company statements.

NU SKIN ENTERPRISES, INC. (NUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Nu Skin Enterprises Reports Second Quarter Results PROVO, Utah — Aug. 10, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results. Executive Summary Q2 2026 vs. Prior-year Quarter Revenue $320.1 million; (17.1)% • (1.0